Drugs / PQ
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02802501 Background | Apr 2018 → Aug 2019 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02802501 ↗ |